AHAlan Hruza

Alan Hruza

*This is an algorithmically generated author record based on publicly available information.

Alan Hruza has a total of 182 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The evolving role of structural biology in pharma: integration of X-ray crystallography, cryo-electron microscopy and beyond

    by Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, et al.

    Structural biology has fundamentally influenced pharmaceutical research and development at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, progressing from pioneering macromolecular crystallography in the 1980s to a fully integrated platform that today encompasses X-ray crystallography, cryo-electron microscopy, micro-electron diffraction and cryo-electron tomography. In this review, we present a comprehensive overview of how these complementary methods have advanced drug discovery across diverse therapeutic areas. We illustrate how atomic to cellular structural insights inform drug discovery and development, from target identification and validation, hit finding, lead identification through lead optimization and clinical progression. Furthermore, we describe how structural biology techniques aid in formulation strategies of antibodies and vaccines. Finally, we highlight the growing integration of ex situ and in situ approaches as a paradigm shift towards elucidating drug mechanisms in native cellular contexts, a transition poised to accelerate the discovery and development of next-generation therapeutics.

  • Top Cited Papers

    Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide

    by Artis Klapars, Anna Fryszkowska, Stephanie Galanie, Omer Ad, Ellen Y. Aguilera, Nnamdi Akporji, Chihui An, Stephanus Axnanda, Tewoderos M. Ayele, Richard S. Ayikpoe, et al.

    Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.